2.Design and practice of the "two-stage & two-model" practice teaching
Zhanqi WANG ; Fei SUN ; Zheng QIAN ; Yue GAO ; Dezeng ZHU ; Ping JIANG
Chinese Journal of Medical Education Research 2006;0(11):-
To improve the quality of personnel training,carry out the complementary ascendancy and resource sharing,grasp the law and optimize the program of practice teaching,we designed the undergraduate practice teaching of 9 disciplines including clinical medicine,biotechnology,pharmacy,etc.,formulated the practice teaching pattern named "two-stage & two-model",and carried out the practice teaching step by step. The results show that the profession level and overall quality of students have been improved.
3.A clinical analysis of 61 cases of protein-losing enteropathy
Liming ZHU ; Gang SUN ; Jiaming QIAN ; Xiucai FANG ; Guijun FEI ; Huijun SHU ; Tao GUO ; Yue LI
Chinese Journal of Internal Medicine 2011;50(3):209-211
Objective To increase the understanding in protein-losing enteropathy (PLE).Methods Sixty-one PLE patients were enrolled in the study and the clinical characteristics, complicated disease, diagnosis and treatment were analyzed. Results The age of the patients was 16-77 (40±15)years, and the gender ratio was 35:26 (female: male). The main clinical manifestations were bilateral lower limb edema in 51 cases, ascites in 41 cases, bilateral pleural effusion in 23 cases, pericardial effusion in 13cases, abdominal pain in 16 cases and diarrhea in 33 cases. The prominent abnormality in laboratory examinations was hypoalbuminemia. The underlying diseases include systemic lupus erythematosus (SLE) in 28 cases, intestinal lymphangiectasia in 12 cases, hepatic cirrhosis in 5 cases, heart diseases in 5 cases,Crohn's disease in 3 cases, membranous nephropathy in 2 cases, Budd-Chiari syndrome in 1 case. Four cases happened after abdominal operation and 1 case after radiation therapy of gastric cardia cancer. Thirtyseven cases were diagnosed by 99Tcm-labelled human serum albumin scintigraphy and 24 cases were diagnosed clinically. Treatment was focused on underlying diseases. The clinical manifestations in 21 cases of SLE improved after SLE was controlled. In 2 cases of intestinal lymphangiectasia and one with Crohn's disease, the clinical manifestations improved after surgery. The other patients had no improvement.Conclusions PLE was not uncommon in clinical practice. Its predominant characteristics were severe hypoalbuminemia, edema and dropsy of serous cavity. PLE can complicate other diseases such as SLE,intestinal lymphangiectasia. Treatment should be focused on primary disease.
4.Preparation and in vitro evaluation of borneol and folic acid co-modified doxorubicin loaded PAMAM drug delivery system.
Jing-jing LI ; Man-man GUO ; Shun-ping HAN ; Yue SUN ; Wei-dong FEI ; Xiu-iing XU ; Fan-zhu LI
Acta Pharmaceutica Sinica 2015;50(7):899-905
A novel targeting drug carrier (FA-BO-PAMAM) based on the PAMAM G5 dendrimer modified with borneol (BO) and folic acid (FA) molecules on the periphery and doxorubicin (DOX) loaded in the interior was designed and prepared to achieve the purposes of enhancing the blood-brain barrier (BBB) transportation and improving the drug accumulation in the glioma cells. 1H NMR was used to confirm the synthesis of FA-BO-PAMAM; its morphology and mean size were analyzed by dynamic light scattering (DLS) and transmission electron microscope (TEM). Based on the HBMEC and C6 cells, cytotoxicity assay, transport across the BBB, cellular uptake and anti-tumor activity in vitro were investigated to evaluate the properties of nanocarriers in vitro. The results showed that the nanocarrier of FA-BO-PAMAM was successfully synthesized, which was spherical in morphology with the average size of (22.28 ± 0.42) nm, and zeta potential of (7.6 ± 0.89) mV. Cytotoxicity and transport across the BBB assay showed that BO-modified conjugates decreased the cytotoxicity of PAMAM against both HBMEC and C6 cells and exhibited higher BBB transportation ability than BO-unmodified conjugates; moreover, modification with FA increased the total uptake of DOX by C6 cells and enhanced the cytotoxicity of DOX-polymer against C6 cells. Therefore, FA-BO-PAMAM is a promising nanodrug delivery system in employing PAMAM as a drug carrier and treatment for brain glioma.
Biological Transport
;
Blood-Brain Barrier
;
Bornanes
;
chemistry
;
Cell Line, Tumor
;
Dendrimers
;
Doxorubicin
;
pharmacology
;
Drug Carriers
;
chemistry
;
Drug Delivery Systems
;
Folic Acid
;
chemistry
;
Glioma
;
Humans
5.Megastigmanes from an aqueous extract of Uncaria rhynchophylla
Le-ling SONG ; Yue WANG ; Ruo-fei LI ; Cheng-gen ZHU ; Qing-lan GUO ; Jian-gong SHI
Acta Pharmaceutica Sinica 2022;57(6):1832-1839
Five new megastigmanes (
6.Association of +45 and +276 polymorphisms in the adiponectin gene with the development of Kawasaki disease.
Miao HUANG ; Guo-Qing DONG ; Fei XIAO ; Yue-Yue SU ; Ming-Zhu LI
Chinese Journal of Contemporary Pediatrics 2018;20(7):549-553
OBJECTIVETo investigate the distribution of adiponectin +45T/G and +276G/T polymorphisms and its association with the development of Kawasaki disease and coronary artery lesion (CAL).
METHODSA total of 81 children with Kawasaki disease (among whom 11 had CAL) and 100 normal children who underwent physical examination (control group) were enrolled in a case-control study. Sequencing was performed to investigate the distribution of adiponectin +45T/G and +276G/T polymorphisms.
RESULTSThere were no significant differences between the Kawasaki disease and control groups in the frequencies of TT, TG, and GG genotypes and T/G alleles of +45T/G polymorphism in the adiponectin gene (P>0.05). In the Kawasaki disease group, there were also no significant differences in the genotype and allele frequencies of the +45T/G polymorphism between the children with CAL and those without (P>0.05). There were significant differences between the Kawasaki disease and control groups in the frequencies of GG, GT, and TT genotypes and G/T alleles of +276G/T polymorphism in the adiponectin gene (P<0.05). GG genotype was a risk factor for the development of Kawasaki disease (OR=2.313, P=0.006). In the Kawasaki disease group, there was no significant difference in the genotype distribution of the +276G/T polymorphism between the children with CAL and those without (P>0.05).
CONCLUSIONSThe adiponectin +276G/T polymorphism may be associated with the development of Kawasaki disease, but not associated with CAL. The adiponectin +45T/G polymorphism may not be associated with Kawasaki disease or CAL.
Adiponectin ; genetics ; Case-Control Studies ; Child ; Female ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Humans ; Male ; Mucocutaneous Lymph Node Syndrome ; genetics ; Polymorphism, Single Nucleotide
7.Progress on pharmacokinetic study of antibody-drug conjugates.
Jian-jun GUO ; Ran GAO ; Teng-fei QUAN ; Ling-yu ZHU ; Ben SHI ; Yong-yue ZHAO ; Jing ZHU ; Meng-sha LI ; Hai-zhi BU
Acta Pharmaceutica Sinica 2015;50(10):1203-1209
Antibody-drug conjugate (ADC) is a new class of therapeutics composed of a monoclonal antibody and small cytotoxin moieties conjugated through a chemical linker. ADC molecules bind to the target antigens expressed on the tumor cell surfaces guided by the monoclonal antibody component. The binding ADC molecules can be internalized and subsequently the toxin moieties can be released within the tumor cells via chemical and/or enzymatic reactions to kill the target cells. The conjugation combines the merits of both components, i.e., the high target specificity of the monoclonal antibody and the highly potent cell killing activity of the cytotoxin moieties. However, such complexities make the pharmacokinetic and metabolic studies of ADCs highly challenging. The major challenges should include characterization of absorption, distribution, metabolism and excretion, investigation of underlying mechanisms, assessment of pharmacokinetic- pharmacodynamic relationship, and analytical method development of ADC drugs. This review will discuss common pharmacokinetic issues and considerations, as well as tools and strategies that can be utilized to characterize the pharmacokinetic and metabolic properties of ADCs.
Antibodies, Monoclonal
;
pharmacokinetics
;
Cytotoxins
;
pharmacokinetics
;
Humans
;
Immunoconjugates
;
pharmacokinetics
;
Neoplasms
;
drug therapy
8.An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia.
Er-Qing WEI ; Chao-Yang ZHU ; Qiu-Qin XU ; Yue-Ping YU ; Ye-Fei ZHU ; Min-Zhi ZHENG
Acta Physiologica Sinica 2003;55(6):742-747
The purpose of this study was to develop a quantitative and objective method for evaluating neurological deficits in mice with focal cerebral ischemia. After middle cerebral artery occlusion (MCAO), the neurological deficits were evaluated 24 h later. We measured the mean angles, dominant angles and turns in a hanged test in which the mice were sticked on the wall, and the holding angles in an inclined plane test as well, Then we determined the cerebral infarct volumes, neuron density in hippocampus, cortex and subcortical areas 24 h after MCAO. The correlations among infarct volume, neuron density and neurological deficits were analyzed. We also compared the quantitative method with two typical complex methods of behavioral assessment. The effect of [pranlukast, 4-oxo-8-[p-(4-phenylbutyloxy) benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate] (ONO-1078), a neuroprotective agent, on ischemic injury was observed using this method. We found that the variables measured by both quantitative and typical behavioral methods significantly changed in the ischemic mice, and correlated with the infarct volumes and neuron densities. The quantitative variables well correlated with those of typical behavioral assessment, too. ONO-1078 inhibited ischemic injury and reduced the total scores of quantitative assessment. Thus, the quantitative method we developed is useful in evaluating neurological deficits of focal cerebral ischemia with the advantages of objectivity, quantification, simplicity and non-invasion, and can be used in the evaluation of neuroprotective effects of drugs.
Animals
;
Behavior, Animal
;
Brain
;
pathology
;
physiopathology
;
Brain Ischemia
;
etiology
;
pathology
;
physiopathology
;
Chromones
;
pharmacology
;
therapeutic use
;
Female
;
Hippocampus
;
pathology
;
Infarction, Middle Cerebral Artery
;
complications
;
pathology
;
physiopathology
;
Leukotriene Antagonists
;
pharmacology
;
therapeutic use
;
Male
;
Mice
;
Mice, Inbred ICR
;
Neurologic Examination
;
Neuroprotective Agents
;
pharmacology
;
therapeutic use
9.Correlation between iodine nutritional status and thyroid hormone levels of pregnant women in Guanshan Lake District of Guiyang
Wenyuan ZHU ; Fei XIANG ; Hongfen YANG ; Yingmei LIANG ; Yue DING ; Guiwen TANG ; Zhengjun ZHANG ; Li WANG
Chinese Journal of Endemiology 2018;37(1):54-58
Objective To investigate the relationship between iodine nutritional status and thyroid hormone levels,and to provide a guideline for monitoring iodine nutrition and thyroid function.Methods A crosssectional survey was performed by randomly selecting 341 samples (health pregnant women with a first child) from the Second People's Hospital of Guiyang,Bihai Community Medical Center and Jinhuayuan Community Center from October 2015 to September 2016.Levels of serum hormones and antibodies relative to throid of pregnant women in Guanshan Lake District of Guiyang at different pregnant times,which included throid stimulating hormone (TSH),free three triiodothyronine (FT3),free thyroxine (FT4),thyroid peroxidase antibody (TPOAb),and thyroglobulin antibody (TgAb),were measured by the electrochemical luminescence method,and urinary iodine levels were measured by heat digestion.Results The median urinary iodine of pregnant women at early,middle and late stages (T1,T2 and T3 stages) were 191.8,198.9 and 214.5 μg/L,respectively.FT3 increased first and then decreased during pregnancy.Levels of FT3 in the T2 stage were significandy higher than those in T1 and T3 stages (FT3 medians at the three stages were 4.49,4.83 and 4.57 pmol/L),and the differences were statistically significant (P < 0.05).FT4 levels decreased during pregnancy (FT4 medians at the three stages were 16.32,14.65 and 13.22 pmol/L),and the differences among the three groups were statistically significant (H =67.517,P < 0.01).Statistically significant differences were not found in the TSH levels among the three groups ~SH medians at the three stages were 2.05,2.01 and 2.39 mU/L,H =1.297,P > 0.05).The medians of TPOAb and TgAb during T2 stage (9.60 and 19.02 U/ml) were significantly lower than those of other groups (18.92 and 24.75 U/ml at stage T1,and 13.46 and 22.06 U/ml at stage T3),and the differences were statistically significant (P < 0.05).TSH levels were consistent with urinary iodine levels.TSH levels in the excessive iodine group (urine iodine:250 ~ 499 μg/L,2.54 mU/L) were significantly higher than those in the adequate iodine group (urine iodine:150 ~ 249 μg/L,1.97 mU/L) and deficient iodine group (urine iodine:< 150 μg/L,1.91 mU/L),and the differences were statistically significant (P < 0.05).No correlations were found between levels of FT3,FT4,TPOAb,TgAb and levels of the urinary iodine.There was a significant positive correlation between urinary iodine levels and TSH levels (rs =0.180,P < 0.01).The incidence of abnormal thyroid function in pregnant women was 29.33% (100/341),which was composed of clinical hypothyroidism (accounting for 0.88%,3/341),subclinical hypothyroidism (accounting for 25.51%,87/341),low T4 level (accounting for 1.76%,6/341),clinical hyperthyroidism (accounting for 0.59%,2/341),subclinical hyperthyroidism (accounting for 0.59%,2/341),and TPOAb positive and TgAb positive (accounting for 12.61%,43/341).These abnormalities occurred mainly in the T1 and T3 stages.The prevalence of subclinical hypothyroidism increased with increasing of urinary iodine level,and the difference was statistically significant (x2 =11.269,P < 0.05).Conclusion There is a positive correlation between pregnancy iodine nutritional status and its TSH level,so it is important to monitor the level of urinary iodine during pregnancy and to screen the thyroid function and antibodies in the early and middle time of pregnancy.
10.Pathogenic and clinical characteristics of hospitalized children with hand-foot-and-mouth disease
Xi-Tao ZHOU ; Peng-Cheng XIAO ; Li-Yi ZENG ; Yun-Zhu LONG ; Xia LV ; Fei-Yue XIAO
Chinese Journal of Infection Control 2017;16(11):1069-1073
Objective To understand the pathogenic distribution and epidemiological trend of hand-foot-and-mouth disease (HFMD),and provide evidence for the prevention and control of HFMD.Methods Children who were diagnosed with HFMD in a hospital between January and December 2015 were investigated,real time fluorescence PCR was used to detect enterovirus universal type EV,enterovirus 71 (EV71),and Coxsackievirus A16 (CoxA16) in specimens from children with HFMD.Positive rates and distribution of various types of EV among children of different months,genders,age groups,and infection types were analyzed.Results A total of 837 throat swab specimens from HFMD children were collected in 2015,380 (45.40%) of which were EV positive specimens.Virus typing showed that 110 (28.95 %),7 (1.84 %),6(1.58 %),and 257(67.63 %) were positive specimens for EV71,CoxA16,EV71 + CoxA16,and other types of EV.HFMD had a high prevalence since April,reached a peak in May-June,and remained high incidence in July-December.Positive rates of EV in children of different months were statistically different (P<0.05).The age of onset was mainly in children under 3 years.Positive rates of EV and constitute ratios of different types of EV in children of different age groups were all statistically different (all P<0.05).The positive rate of EV in severe HFMD cases was higher than common cases (65.34% vs 27.06%,P<0.001).The proportion of severe cases in children with EV71 infection and other types of EV infection were 90.00% and 60.70% respectively;children with EV71 + CoxA16 double infection were all severe cases.Constitute of EV types in children with different infection types was statistically different(P<0.001).Conclusion In 2015,EV infection in hospitalized children with HFMD in this hospital was mainly caused by other types of EV (nonEV71 and non-CoxA16),the high prevalence season,high-risk population under 3 years of age,and severe cases should be paid high attention,prevention and treatment should be performed well.